ALTRIXA OB- beta-crotene, ascorbic acid, cholecalciferol, dl-alpha tocopherol acetate, pyridoxine hci, biotin, folic acid and I-5 mthf ca salt, cyanocobalamin, calcium carbonate, megnesium oxide, ferrous fumarate, postassium iodide, thiamin hci tablet Allegis Pharmaceuticals. Inc

Altrixa OB Tablets PRENATAL/POSTNATAL Dietary Supplement

Altrixa OB Tablets - Dispensed by Prescription

Serving Size: 1 Tablet		
Servings Per Container: 30		
Each Tablet Contains:		%DV
Vitamin A (as beta-carotene)	300 mcg RAE	66%
Vitamin C (as ascorbic acid)	125 mg	140%
Vitamin D3 (as cholecalciferol)	12.5 mcg	30%
Vitamin E (as dl-alpha-tocopheryl acetate)	4.5 mg	33%
Vitamin B6 (as pyridoxine HCl)	20 mg	1117%
Folate	1750 mcg DFE	437.5%
(From 588 mcg folic acid		
and 442 mcg L-5 MTHF ca salt)		
Vitamin B12 (as cyanocobalamine)	0.03 mg	650%
Biotin	30 mg	10%
Calcium (from calcium carbonate)	100 mg	7.5%
lron (as ferrous fumarate)	15 mg	83%
lodine (as potassium iodide)	150 mcg	100%
Magnesium (as magnesium oxide)	20 mg	5%
Thiamin (as thiamin HCI)	•	1.4
mg 100%		

** Daily Values (DV) not established.

OTHER INGREDIENTS: Microcrystalline cellulose, powdered cellulose, silica, vegetable steric acid, croscarmellose sodium, vegetable magnesium stearate, coating (hypromellose, hydroxypropyl cellulose, titanium dioxide, polyehylene glycol).

Description

Altrixa OB Tablets is a prescription dietary supplement for use throughout pregnancy, during the postnatal period for both lactating and non-lactating mothers, and throughout the childbearing years.

Prenate Max Tablets may be useful in improving the nutritional status of women prior to conception.

CONTRADINDICATIONS

Altrixa OB Tablets are contraindicted in patients with a known hypersensitivity to any of the contained ingredients. Do not take this product if you are presently taking mineral oil, unless directed by a licensed medical practitioner.

WARNING

Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHILDREN. In the case of accidental overdose, call a doctor or poison control center immediately.

ADVERSE REACTIONS

Allergic sensitization has been reported following both oral and parenteral administration of folic acid.

You may report side effects by calling Allegis Pharmaceuticals, Inc at 1-866-633-9033 or the FDA by calling 1-800-FDA-1088.

DOSAGE AND ADMINISTRATION

Before, during and/or after pregnancy, one tablet daily with food or as directed by a physician.

PRECAUTION:

Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where Vitamin B12 is deficient. Folic acid in doses above 0.1 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations progress. Prenate Max Tablets should only be used under the direction and supervision of a licensed medical practioner.

For use under the supervision of a licensed medical practitioner. Dispense in a tight, light resistant container as defined in the USP/NF in a child-resistant closure.

How Supplied

How Supplied

Altrixa OB Talets are available as white tablets with "225" embossed and are available in 30 count bottles (28595-721-30*).

Manufactured in the USA for:

Allegis Pharmaceuticals, Inc.

Canton, MS 39046

Rev 05/2025

Statements

These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

This product is not an Orange Book Product.

Dispense by Prescrition**

*Allegis Pharmaceuticals, Inc. does not represent these product codes to be National Drug Codes (NDC). Product codes are formated according to standard industry practice, to meet the formatting requirements by pedigree reporting and supply-chain control including pharmacies.

** This product is a prescription-folate with or without other dietary ingredients that due to increased folate levels increased risk associated with masking of B12 deficiency (pernicious anemia) requires administratin under the care of a licensed medical practitioner (61 FR 8760).1-3 The most appropriate way to ensure pedigree reporting consistent with these regulatory guidelines and safety monitoring is to dispense this product only by prescription. This is not an Orange Book product. This product may be administered only under a physician's supervision and all prescriptions using this product shall be pursuant to state statutes as applicable. The ingredients, indication or claims of this product are not to be construed to be a drug claims.

- 1. Federal Register Notice of August 2, 1973 (38 FR 20750)
- 2. Federal Register Notice of October 17, 1980 (45 FR 69043, 69044)
- 3. Federal Register Notice of March 5, 1996 (61 FR 8760)

STORAGE

Store at 20°-25°C (68°-77°F) excursions permitted to 15°-30°C (59°-86°F) [See USP Controlled Room Temperature.] Protect from light and moisture.

Tamper evident: Do not use if seal is broken or missing.

Label

28595-721-30 ALTRIXA OB Tablets	0e	% Daily Value	ľ			-	10% 10%	DFE 437.5%	mg 650%		mg 5%		1cg 100%	mg 100%	20	
Prenatal/Postnatal	cts Servings	0 mcn RAF	125 mg	12.5 mcg	4.5 mg	20 mg	30 mcg	1750 mcg	0.03 mg	100 mg	20 mg	15 mg	150 mcg	1.4		for:
Dietary Supplement Dispensed by Prescription	nent Fac	Amount Per Serving: Vitamin A (as Beta-carntene) 300	C (as Ascorbic Acid)	D3 (a	/itamin E (as dI-Alpha Tocopherol Acetate)	fitamin B6 (as Pyridoxine HCI)	liotin	Folate (from 588 mcg folic acid and 442 mcg L-5 MTHF ca Salt)	(itamin B12 (as cyanocobalamin)	alcium (as Calcium carbonate)	Magnesium (as Magnesium Oxide)		odine (as Potassium Iodide)	Thiamin (as Thiamin HCI)	**Daily Values (DV) not established.	Manufactured in the USA for Allegis Pharmaceuticals, Inc. Canton, MS 39046 Rev. 05/2025

6

2859

M

ALTRIXA OB

beta-crotene, ascorbic acid, cholecalciferol, dl-alpha tocopherol acetate, pyridoxine hci, biotin, folic acid and I-5 mthf ca salt, cyanocobalamin, calcium carbonate, megnesium oxide, ferrous fumarate, postassium iodide, thiamin hci tablet

Product Information									
Product Type	DIETARY SUPPLEMENT	Item Code (Source)	NHRIC:28595-721						
Route of Administration	ORAL								

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
ASCORBIC ACID (UNII: PQ6CK8PD0R) (ASCORBIC ACID - UNII:PQ6CK8PD0R)	ASCORBIC ACID	125 mg
BETA CAROTENE (UNII: 01YAE03M7J) (BETA CAROTENE - UNII:01YAE03M7J)	BETA CAROTENE	300 ug
CHOLECALCIFEROL (UNII: 1C6V77QF41) (CHOLECALCIFEROL - UNII:1C6V77QF41)	CHOLECALCIFEROL	12.5 ug
.ALPHATOCOPHEROL ACETATE, DL- (UNII: WR1WPI7EW8) (.ALPHATOCOPHEROL, DL UNII:7QWA1RIO01)	.ALPHA TOCOPHEROL, DL-	4.5 mg
PYRIDOXINE HCL (UNII: 68Y4CF58BV) (PYRIDOXINE - UNII:KV2JZ1BI6Z)	PYRIDOXINE	20 mg
FOLIC ACID (UNII: 935E97BOY8) (FOLIC ACID - UNII:935E97BOY8)	FOLIC ACID	1750 ug
CYANOCOBALAMIN (UNII: P6YC3EG204) (CYANOCOBALAMIN - UNII:P6YC3EG204)	CYANOCOBALAMIN	0.03 mg
BIOTIN (UNII: 6SO6U10H04) (BIOTIN - UNII:6SO6U10H04)	BIOTIN	30 ug
CALCIUM CARBONATE (UNII: H0G9379FGK) (CALCIUM CATION - UNII:2M83C4R6ZB)	CALCIUM CATION	100 mg
FERROUS BISGLYCINATE (UNII: SFW1D987QV) (FERROUS CATION - UNII:GW895810WR)	FERROUS CATION	15 mg
POTASSIUM IODIDE (UNII: 1C4QK22F9J) (IODIDE ION - UNII:09G4I6V86Q)	IODIDE ION	150 ug
MAGNESIUM OXIDE (UNII: 3A3U0GI71G) (MAGNESIUM CATION - UNII:T6V3LHY838)	MAGNESIUM CATION	20 mg
THIAMINE (UNII: X66NSO3N35) (THIAMINE ION - UNII:4ABT0J945J)	THIAMINE	1.4 mg

Inactive Ingredients								
Ingredient Name								
MICROCRYSTALLINI		OSE (UNII: OP1R32D61U)						
CELLULOSE ACETA	re (unii: 3	BJ2P07GVB6)						
SILICA (UNII: ETJ7Z6XBU4)								
STEARIC ACID (UNII:	4ELV7Z6	5AP)						
CROSCARMELLOSE	SODIUM	(UNII: M28OL1HH48)						
MAGNESIUM STEAR	ATE (UNII	: 70097M6I30)						
HYPROMELLOSE, U	NSPECIFI	ED (UNII: 3NXW29V3WO)						
HYDROXYPROPYL C	ELLULOS	E, UNSPECIFIED (UNII: 9)	XZ8H6N6OH)					
TITANIUM DIOXIDE (UNII: 15FIX9V2JP)								
TITANIUM DIOXIDE	(UNII: 15F	IX9V2JP)						
		IX9V2JP) ISPECIFIED (UNII: 3WJQ0S	DW1A)					
		•	DW1A)					
		•	DW1A)					
POLYETHYLENE GLY		•	DW1A)					
POLYETHYLENE GLY Packaging	COL, UN	•		g Start Date	Mar	keting End Date		
POLYETHYLENE GL Packaging # Item Code	rcol, UN Pa	ISPECIFIED (UNII: 3WQOS		g Start Date	Mar	keting End Date		
POLYETHYLENE GLY Packaging	rcol, UN Pa	SPECIFIED (UNII: 3WQOS		g Start Date	Mar	keting End Date		
POLYETHYLENE GL Packaging # Item Code	rcol, UN Pa	SPECIFIED (UNII: 3WQOS		g Start Date	Marl	keting End Date		
POLYETHYLENE GLY Packaging # Item Code 1 NHRIC:28595-721-3	(COL, UN Pa 30 30 ir	SPECIFIED (UNII: 3WQOS Ackage Description 1 BOTTLE		g Start Date	Mar	keting End Date		
POLYETHYLENE GLY Packaging # Item Code 1 NHRIC:28595-721-3 Marketing II	rcol, UN Pa 30 30 ir nform	ackage Description 1 BOTTLE	Marketin					
POLYETHYLENE GLY Packaging # Item Code 1 NHRIC:28595-721-3	rcol, UN Pa 30 30 ir nform	SPECIFIED (UNII: 3WQOS Ackage Description 1 BOTTLE	Marketin	g Start Date Marketing St Date		keting End Date Marketing End Date		
POLYETHYLENE GLY Packaging # Item Code 1 NHRIC:28595-721-3 Marketing II Marketing	rcol, UN Pa 30 30 ir nform	ackage Description 1 BOTTLE ation	Marketin	Marketing St		Marketing End		

Supplement Facts							
Serving Size :		Serving per Container :					
	Amount Per Serving	% Daily Value					
color							
shape							
imprint							
size (solid drugs)	19 mm						
scoring	1						

Labeler - Allegis Pharmaceuticals, Inc (792272861)

Revised: 5/2025

Allegis Pharmaceuticals, Inc